Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

[1]  T. Jenuwein.  The epigenetic magic of histone lysine methylation , 2006, The FEBS journal.

[2]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[3]  Danny Reinberg,et al.  Histone Lysine Demethylases and Their Impact on Epigenetics , 2006, Cell.

[4]  Kelly M. McGarvey,et al.  Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. , 2006, Cancer research.

[5]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[6]  H. Cedar,et al.  G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis , 2006, Nature Cell Biology.

[7]  Axel Imhof,et al.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 , 2005, Nature chemical biology.

[8]  Tsutomu Ohta,et al.  Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. , 2005, Genes & development.

[9]  Martin Radolf,et al.  The profile of repeat‐associated histone lysine methylation states in the mouse epigenome , 2005, The EMBO journal.

[10]  J. Issa,et al.  Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents , 2005, Cancer investigation.

[11]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[12]  A. Roopra,et al.  Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. , 2004, Molecular cell.

[13]  Randall W King,et al.  Small Molecule Regulators of Protein Arginine Methyltransferases* , 2004, Journal of Biological Chemistry.

[14]  Shi Huang,et al.  Inactivation of a histone methyltransferase by mutations in human cancers. , 2003, Cancer research.

[15]  Yi Zhang,et al.  mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. , 2003, Molecular cell.

[16]  E. Selker,et al.  Structural basis for the product specificity of histone lysine methyltransferases. , 2003, Molecular cell.

[17]  E. Heard,et al.  Role of Histone Methyltransferase G9a in CpG Methylation of the Prader-Willi Syndrome Imprinting Center* , 2003, The Journal of Biological Chemistry.

[18]  Andrew J. Bannister,et al.  Unsafe SETs: histone lysine methyltransferases and cancer. , 2002, Trends in biochemical sciences.

[19]  H. Kato,et al.  G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. , 2002, Genes & development.

[20]  Shi Huang.  Histone methyltransferases, diet nutrients and tumour suppressors , 2002, Nature Reviews Cancer.

[21]  David M. Livingston,et al.  A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G0 Cells , 2002, Science.

[22]  D. Reinberg,et al.  Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. , 2002, Genes & development.

[23]  Hengbin Wang,et al.  Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. , 2001, Molecular cell.

[24]  Brian D. Strahl,et al.  Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1 , 2001, Current Biology.

[25]  C. Ponting,et al.  Regulation of chromatin structure by site-specific histone H3 methyltransferases , 2000, Nature.

[26]  G. Weidinger.  Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. , 1995, Arzneimittel-Forschung.

[27]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[28]  G. Schotta,et al.  Trilogies of histone lysine methylation as epigenetic landmarks of the eukaryotic genome. , 2004, Cold Spring Harbor symposia on quantitative biology.

[29]  R. Jaenisch,et al.  Nuclear transplantation, embryonic stem cells, and the potential for cell therapy. , 2003, The New England journal of medicine.

[30]  W. Nawrocka.  Syntheses and pharmacological properties of new 2-aminobenzimidazole derivatives. , 1996, Bollettino chimico farmaceutico.